New vaccine targets group b strep in seniors

NCT ID NCT05782179

Completed ⭐️ VACCINE ⭐️ Sponsor: Minervax ApS Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-stage trial tested a new vaccine against Group B Streptococcus (GBS) in 90 healthy adults aged 55 to 75. Participants received three doses of the vaccine or a placebo, and researchers monitored safety and immune response for six months. The goal is to see if the vaccine is safe and triggers a strong immune defense against GBS, which can cause severe infections in older adults.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Group B Streptococcus vaccine (GBS-NN/NN2 with alhydrogel adjuvant)
What this could lead to: If successful, this could lead to a vaccine that protects older adults from Group B Strep infections, which can cause serious illness.
What could go wrong: This is an early Phase 1 trial with only 90 participants, so safety and immune response are still being tested. It may not work in larger, more diverse groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GROUP B STREPTOCOCCAL INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

group B streptococcal infection obesity disorder streptococcal infection type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GROUP B STREPTOCOCCAL INFECTIONS

Contacts and locations

Locations

University Hospital Ghent - Centrum voor Vaccinologie (CEVAC) department

Ghent, 9000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.